Arecor Therapeutics plc Stock price

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:22 2024-02-22 am EST 5-day change 1st Jan Change
145 GBX -1.69% Intraday chart for Arecor Therapeutics plc -6.45% -20.55%
Sales 2023 * 5.01M 6.34M Sales 2024 * 7.58M 9.59M Capitalization 45.17M 57.12M
Net income 2023 * -6M -7.59M Net income 2024 * -6M -7.59M EV / Sales 2023 * 7.78 x
Net cash position 2023 * 6.17M 7.8M Net cash position 2024 * 2.08M 2.63M EV / Sales 2024 * 5.68 x
P/E ratio 2023 *
-6.15 x
P/E ratio 2024 *
-6.86 x
Employees 51
Yield 2023 *
-
Yield 2024 *
-
Free-Float 48.44%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.69%
1 week-6.45%
Current month-12.65%
1 month-13.95%
3 months-22.04%
6 months-23.68%
Current year-20.55%
More quotes
1 week
140.00
Extreme 140
155.00
1 month
140.00
Extreme 140
170.00
Current year
140.00
Extreme 140
184.00
1 year
140.00
Extreme 140
322.00
3 years
140.00
Extreme 140
472.00
5 years
140.00
Extreme 140
472.00
10 years
140.00
Extreme 140
472.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 -
Director of Finance/CFO 65 18-12-31
Chief Tech/Sci/R&D Officer - 07-07-31
Members of the board TitleAgeSince
Director/Board Member 78 -
Director/Board Member 66 21-04-30
Chairman 64 -
More insiders
Date Price Change Volume
24-02-22 145 -1.69% 5 627
24-02-21 147.5 -2.64% 1,829
24-02-20 151.5 -2.26% 3,250
24-02-19 155 0.00% 0
24-02-16 155 0.00% 3,542

Delayed Quote London S.E., February 22, 2024 at 11:35 am EST

More quotes
Arecor Therapeutics plc is a globally focused biopharmaceutical company. The Company, through its formulation technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver formulations of their therapeutic products. Its clinical development programs include AT247-Ultra-Rapid Acting Insulin and AT278-Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. AT278 is a concentrated formulation of rapid acting insulin that is designed to accelerate the absorption of insulin post injection, even when delivered at a high concentration, and hence via a lower injection volume. It also has Tetris Pharma portfolio.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.475 GBP
Average target price
4.71 GBP
Spread / Average Target
+219.32%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Arecor Therapeutics plc - London S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer